We use high-throughput, high-dimensional approaches to develop therapies for diseases driven by the biology of aging.

The deeper, underlying causes of age-related diseases are the untreated mechanisms of aging itself. By focusing on the cellular drivers of aging, Retro will design therapeutics eventually capable of multi-disease prevention.

Joe Betts-LaCroix, Sheng Ding, and Matt Buckley founded Retro with the intention of building a generational pharma company proportional to the scale of our mission.

In 2023, it was revealed that the major investor was Sam Altman.